Targeted degradation of VEGF with bispecific aptamer-based LYTACs ameliorates pathological retinal angiogenesis
Authors:
Open Access
- 1 January 2024
- journal article
- research article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 14 (13) , 4983-5000
Abstract
Rationale: Neovascular ocular diseases (NODs) represent the leading cause of visual impairment globally. Despite significant advances in anti-angiogenic therapies targeting vascular endothelial growth factor (VEGF), persistent challenges remain prevalent. As a proof-of-concept study, we herein demonstrate the effectiveness of targeted degradation of VEGF with bispecific aptamer-based lysosome-targeting chimeras (referred to as VED-LYTACs).Keywords
This publication has 59 references indexed in Scilit:
- Aptamers evolved from live cells as effective molecular probes for cancer studyProceedings of the National Academy of Sciences of the United States of America, 2006
- Aptamers come of age – at lastNature Reviews Microbiology, 2006
- Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular diseaseNature Reviews Drug Discovery, 2006
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Mannose 6-phosphate receptors: new twists in the taleNature Reviews Molecular Cell Biology, 2003
- Long-term culture of lymphohematopoietic stem cells.Proceedings of the National Academy of Sciences, 1996
- Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I moleculesCell, 1994
- Oxygen-induced retinopathy in the mouse.1994
- Autoimmune destruction of islets transplanted into RT6-depleted diabetes-resistant BB/Wor ratsDiabetes, 1990
- Lysosomes, pH and the Anti-malarial Action of ChloroquineNature, 1972